ClinicalTrials.gg
CompletedNCT06045507Updated Jan 7, 2026Results posted

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

A Phase 2 interventional study of MK-8527 and Placebo to MK-8527 in HIV and HIV Pre-exposure Prophylaxis, sponsored by Merck Sharp & Dohme LLC. Completed at 18 sites in 3 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This double-blind, placebo-controlled study was designed to assess the safety, tolerability, and pharmacokinetics of oral MK-8527 taken once monthly (QM) in participants at low risk for human immunodeficiency virus Type 1 (HIV-1) infection.

02

Conditions studied

  • HIV
  • HIV Pre-exposure Prophylaxis
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is confirmed -uninfected based on negative HIV-1/HIV-2 test result before randomization
  • Has low-risk of HIV infection
  • Females: is not pregnant or breastfeeding and is either not a participant of (POCBP) OR is a POCBP and uses an acceptable or is abstinent from penile-vaginal intercourse

Exclusion criteria

Exclusion Criteria:

  • Has or other to any of the components of the study interventions as determined by the investigator
  • Has an active diagnosis of hepatitis due to any cause, including active (HBV) infection (defined as HBsAg-positive) or virus (HCV) infection (defined as detectable HCV ribonucleic acid [RNA])
  • Prior use of MK-8527 or islatravir (MK-8591)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
352 participants (actual)

Study arms

  • Experimental
    MK-8527 Low Dose QM

    Participants receive oral MK-8527 low dose QM for 6 months, followed by an 8-week blinded safety follow-up period.

    Drug: MK-8527

  • Experimental
    MK-8527 Medium Dose QM

    Participants receive oral MK-8527 medium dose QM for 6 months, followed by an 8-week blinded safety follow-up period.

    Drug: MK-8527

  • Experimental
    MK-8527 High Dose QM

    Participants receive oral MK-8527 high dose QM for 6 months, followed by an 8-week blinded safety follow-up period.

    Drug: MK-8527

  • Placebo comparator
    Placebo to MK-8527

    Participants receive oral placebo matched to MK-8527 QM for 6 months, followed by an 8-week blinded safety follow-up period.

    Drug: Placebo to MK-8527

Interventions

  • MK-8527 capsule

  • DrugPlacebo to MK-8527

    Placebo capsule matched to MK-8527

06

What researchers measure

Primary outcomes

  1. Number of Participants With ≥1 Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to ~28 weeks

  2. Number of Participants Discontinuing Study Therapy Due to Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to ~20 weeks

Secondary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Dosing to Last Measurable Concentration (AUC0-last) of MK-8527

    The plasma AUC0-last of MK-8527 is reported.

    Time frame: Day 1: predose and 0.5, 4, and 24 hours postdose. Week 20: 0.5, 4, and 24 hours postdose

  2. Maximum Plasma Concentration (Cmax) of MK-8527

    The plasma Cmax of MK-8527 is reported.

    Time frame: Day 1: predose and 0.5, 4, and 24 hours postdose. Week 20: 0.5, 4, and 24 hours postdose

07

Results

Posted Jan 7, 2026

Participant flow

Adult participants who were at low risk of human immunodeficiency virus Type 1 (HIV-1) infection were recruited.

Participant flow — Overall Study
MilestoneMK-8527 3 mg QMMK-8527 6 mg QMMK-8527 12 mg QMPlacebo to MK-8527
Started10110210049
Completed92979846
Not completed9523
Withdrew: Death0010
Withdrew: Lost to follow-up3300
Withdrew: Randomized by mistake (no study treatment given)0110
Withdrew: Withdrawal by subject4102
Withdrew: Miscellaneous2001

Outcome measures

PrimaryNumber of Participants With ≥1 Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to ~28 weeks
Reported as:
Count of participants · Participants
Number of Participants With ≥1 Adverse Event (AE)
ParticipantsMK-8527 3 mg QMMK-8527 6 mg QMMK-8527 12 mg QMPlacebo to MK-8527
Number of Participants With ≥1 Adverse Event (AE)62696631
SecondaryArea Under the Plasma Concentration-Time Curve From Dosing to Last Measurable Concentration (AUC0-last) of MK-8527

The plasma AUC0-last of MK-8527 is reported.

Time frame:
Day 1: predose and 0.5, 4, and 24 hours postdose. Week 20: 0.5, 4, and 24 hours postdose
Reported as:
Geometric mean · hr*µmol/L
Area Under the Plasma Concentration-Time Curve From Dosing to Last Measurable Concentration (AUC0-last) of MK-8527
hr*µmol/LMK-8527 3 mg QMMK-8527 6 mg QMMK-8527 12 mg QMPlacebo to MK-8527
Day 10.132 ± 84.80.397 ± 36.10.861 ± 34.1—
Week 200.129 ± 81.50.404 ± 37.30.836 ± 55.0—
PrimaryNumber of Participants Discontinuing Study Therapy Due to Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to ~20 weeks
Reported as:
Count of participants · Participants
Number of Participants Discontinuing Study Therapy Due to Adverse Event (AE)
ParticipantsMK-8527 3 mg QMMK-8527 6 mg QMMK-8527 12 mg QMPlacebo to MK-8527
Number of Participants Discontinuing Study Therapy Due to Adverse Event (AE)0212
SecondaryMaximum Plasma Concentration (Cmax) of MK-8527

The plasma Cmax of MK-8527 is reported.

Time frame:
Day 1: predose and 0.5, 4, and 24 hours postdose. Week 20: 0.5, 4, and 24 hours postdose
Reported as:
Geometric mean · µmol/L
Maximum Plasma Concentration (Cmax) of MK-8527
µmol/LMK-8527 3 mg QMMK-8527 6 mg QMMK-8527 12 mg QMPlacebo to MK-8527
Day 10.0289 ± 69.00.0490 ± 75.60.113 ± 64.5—
Week 200.0320 ± 67.50.0538 ± 73.50.108 ± 72.5—

Adverse events

Collected over Up to ~28 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-8527 3 mg QM0/101 (0%)2/101 (2%)38/101 (37.6%)
MK-8527 6 mg QM0/101 (0%)0/101 (0%)43/101 (42.6%)
MK-8527 12 mg QM1/99 (1%)1/99 (1%)32/99 (32.3%)
Placebo to MK-85270/49 (0%)1/49 (2%)21/49 (42.9%)
Most frequent serious events
Most frequent serious events
EventMK-8527 3 mg QMMK-8527 6 mg QMMK-8527 12 mg QMPlacebo to MK-8527
OsteoarthritisMusculoskeletal and connective tissue disorders0/1010/1010/991/49
Gun shot woundInjury, poisoning and procedural complications0/1010/1011/990/49
Abdominal painGastrointestinal disorders1/1010/1010/990/49
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/1010/1010/990/49
Most frequent other events
Showing 10 of 11
Most frequent other events
EventMK-8527 3 mg QMMK-8527 6 mg QMMK-8527 12 mg QMPlacebo to MK-8527
Upper respiratory tract infectionInfections and infestations16/10110/10110/996/49
HeadacheNervous system disorders9/1017/1011/990/49
NasopharyngitisInfections and infestations3/1012/1012/994/49
NauseaGastrointestinal disorders4/1018/1013/991/49
FatigueGeneral disorders5/1018/1017/993/49
CoughRespiratory, thoracic and mediastinal disorders5/1017/1011/990/49
Blood creatine phosphokinase increasedInvestigations3/1011/1013/993/49
Lymphocyte count decreasedInvestigations0/1011/1016/991/49
COVID-19Infections and infestations2/1014/1015/992/49
CD4 lymphocytes decreasedInvestigations4/1013/1015/991/49

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MK-8527 3 mg QMMK-8527 6 mg QMMK-8527 12 mg QMPlacebo to MK-8527Total
Mean30.4 ± 10.1230.0 ± 9.8029.6 ± 8.8429.8 ± 8.9030.0 ± 9.48
Sex: Female, Male
Sex: Female, Male(Participants)MK-8527 3 mg QMMK-8527 6 mg QMMK-8527 12 mg QMPlacebo to MK-8527Total
Female58595829204
Male43424120146
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MK-8527 3 mg QMMK-8527 6 mg QMMK-8527 12 mg QMPlacebo to MK-8527Total
Hispanic or Latino1813141156
Not Hispanic or Latino83868438291
Unknown or Not Reported02103
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MK-8527 3 mg QMMK-8527 6 mg QMMK-8527 12 mg QMPlacebo to MK-8527Total
American Indian or Alaska Native00000
Asian32308
Native Hawaiian or Other Pacific Islander00000
Black or African American44404021145
White49545126180
More than one race00000
Unknown or Not Reported555217
08

Study locations

18 sites
  • Velocity Clinical Research, North Hollywood ( Site 0054)
    North Hollywood, California 91606, United States
  • Bridge HIV- San Francisco Department of Public Health ( Site 0042)
    San Francisco, California 94102, United States
  • Velocity Clinical Research, Hallandale Beach ( Site 0052)
    Hallandale, Florida 33009, United States
  • Community Medical Care Center ( Site 0056)
    Immokalee, Florida 34142, United States
  • Velocity Clinical Research Rockville ( Site 0048)
    Rockville, Maryland 20854, United States
  • Fenway Health ( Site 0043)
    Boston, Massachusetts 02215, United States
  • Albuquerque Clinical Trials, Inc. ( Site 0044)
    Albuquerque, New Mexico 87102, United States
  • University of Pittsburgh Medical Center-Division of Infectious Diseases ( Site 0041)
    Pittsburgh, Pennsylvania 15213, United States
  • Prism Health North Texas, Oak Cliff Health Center ( Site 0045)
    Dallas, Texas 75208, United States
  • Fred Hutchinson Cancer Center - The Seattle HIV Vaccine Trials Unit ( Site 0057)
    Seattle, Washington 98104, United States
  • Rambam Health Care Campus ( Site 0003)
    Haifa, 3109601, Israel
  • Hadassah Medical Center ( Site 0002)
    Jerusalem, 9112001, Israel
  • Sheba Medical Center ( Site 0001)
    Ramat Gan, 5265601, Israel
  • Josha Research ( Site 0023)
    Bloemfontein, Free State 9301, South Africa
  • Wits RHI-Wits RHI Ward 21 Clinical Research site ( Site 0027)
    Johannesburg, Gauteng 2000, South Africa
  • Helen Joseph Hospital ( Site 0024)
    Johannesburg, Gauteng 2092, South Africa
  • Qhakaza Mbokodo Research Clinic ( Site 0026)
    Ladysmith, KwaZulu-Natal 3370, South Africa
  • Desmond Tutu Health Foundation ( Site 0021)
    Cape Town, Western Cape 7925, South Africa
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Dec 2024, 13 months.

Results were first posted in Jan 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2023
First posted
Sep 21, 2023
StartActual
Nov 8, 2023
Primary completionActual
Dec 12, 2024
CompletionActual
Feb 12, 2025
Results first posted
Jan 7, 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06045507
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Nov 8, 2023
Primary completion
Dec 12, 2024
Completion
Feb 12, 2025
Results posted
Jan 7, 2026
Last update
Jan 7, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alimatravir

Start the discussion